Novo Nordisk (NVO)’s Pediatric Obesity Opportunity Faces a Bigger Test

Novo Nordisk A/S (NYSE: NVO ) looks to open a new growth avenue for its blockbuster obesity drug Wegovy by targeting the pediatric market. In the late-stage STEP Young trial, semaglutide (the active ingredient in Wegovy) produced strong results in young children.

In the trial, 40.4% of children treated with semaglutide were no longer classified as having obesity after 68 weeks, assuming adherence to treatment, compared with none receiving placebo.

The result could expand the addressable market for Wegovy. But investors still need to see whether Novo can convert a successful clinical trial into a meaningful commercial opportunity.

STEP Young Expands the Wegovy Opportunity

The STEP Young trial met its primary endpoint. Semaglutide demonstrated a superior reduction in body mass index at week 68 compared with placebo. But there is an important point to note. In addition to taking semaglutide once weekly, all trial participants also received lifestyle modifications. These included a reduced-calorie diet and increased physical activity.

That aside, the magnitude of the result gives Novo a pathway into a potentially large new market. Although GLP-1 weight-loss drugs are not currently approved for children under 12 in the U.S., a recent study offers a glimpse into the demand. The study, published September 4 in the Pediatrics journal, revealed that GLP-1 weight-loss drug prescribing among children ages 8 to 11 with obesity and without diabetes increased roughly 310-fold from 2019 to 2026.

That demand signal matters. It suggests that Novo is not attempting to create an additional market for its obesity drug from scratch. If regulators approve semaglutide for children and doctors adopt the drug, Novo could extend the commercial life of its leading obesity franchise.

The timing makes the program particularly significant. Novo Nordisk A/S (NYSE:NVO) is attempting to regain ground against Eli Lilly in the lucrative obesity market. Recent pipeline developments have increased pressure on the company to find additional sources of growth.

In the REDEFINE 4 obesity trial, Novo's CagriSema produced 23.0% weight loss after 84 weeks versus 25.5% with Lilly's tirzepatide and failed the trial's primary endpoint of demonstrating non-inferiority on weight loss. CagriSema is Novo's next-generation obesity drug candidate. The result compounded concerns about whether Novo can develop a successor to semaglutide with a strong competitive advantage.

That said, the STEP Young program provides something different. It allows Novo to expand semaglutide into an additional age group rather than relying entirely on a new molecule.